When was Rhythm Pharmaceuticals founded?

Rhythm Pharmaceuticals was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Rhythm Pharmaceuticals located?

Rhythm Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

Who is the current CEO of Rhythm Pharmaceuticals?

David Meeker of Rhythm Pharmaceuticals.

How many employees does Rhythm Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Rhythm Pharmaceuticals is 510.

Is Rhythm Pharmaceuticals a funded company?

Rhythm Pharmaceuticals is a funded company, having raised a total of $84M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 15, 2010.

When was the latest funding round of Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' latest funding was a $***** Post IPO round on Apr 01, 2024, with participation from 1 investor.

What is the annual revenue of Rhythm Pharmaceuticals?

Annual revenue of Rhythm Pharmaceuticals is between $100M and $500M as on Dec 31, 2025

Where does Rhythm Pharmaceuticals rank among its competitors?

Rhythm Pharmaceuticals ranks 9th amongst 323 active competitors, of which 88 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Rhythm Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.

Email ID: *****@rhythmtx.com
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2010

Location

Boston, United States

Stage

Public

Total Funding

$84M in 9 rounds

Latest Funding Round

Post IPO, Apr 01, 2024, $*****

Investors

Third Rock Ventures & 10 more

Ranked

9^th among 323 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

510 as on Sep 30, 2026

Investment & Acquisitions

Xinvento

Similar Companies

BridgeBio & 375 more

Exit Details

Public

View Rhythm Pharmaceuticals' full profile

Rhythm Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RHYTHM PHARMAEUTICALS CIN: 0798.109.961 , Belgium, Active	Feb 01, 2023	-	-	-
Rhythm Pharmaceuticals, Inc. CIN: 1649904 , United States, Active	Feb 25, 2013	$100M - $500M (As on Dec 31, 2025)	-	-
Rhythm Pharmaceuticals Inc CIN: 462159271 , United States, Active	Dec 31, 1999	-	191 (As on Dec 31, 2024)	-

Rhythm Pharmaceuticals got listed on Oct 05, 2017.

Click here to take a look at Rhythm Pharmaceuticals's IPO in detail

Rhythm Pharmaceuticals has raised a total funding of $84M over 9 rounds. Its first funding round was on Mar 15, 2010. Its latest funding round was a Post IPO round on Apr 01, 2024 for $*****. 1 investor participated in its latest round. Rhythm Pharmaceuticals has 11 institutional investors.

Here is the list of recent funding rounds of Rhythm Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2024	6839154	Post IPO	2153028	2657274	9267249	4247422
Feb 16, 2017	9340510	Venture Debt	5111934	2072093	7154019	Deerfield & 4 more
Jul 10, 2015	5284099	Grant (prize money)	6632330	4180675	7912393	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Rhythm Pharmaceuticals's funding rounds and investors

The founders of Rhythm Pharmaceuticals is Bart Henderson. David Meeker is the CEO of Rhythm Pharmaceuticals.

Here are the details of Rhythm Pharmaceuticals' key team members:

Bart Henderson: Former Founder & President of Rhythm Pharmaceuticals and founder of 1 other company.
David Meeker: CEO of Rhythm Pharmaceuticals.
Contact Info: 1 email address

View details of Rhythm Pharmaceuticals's Founder profiles and Board Members

Rhythm Pharmaceuticals' employee count trend

Rhythm Pharmaceuticals has 510 employees as of Sep 26. Here is Rhythm Pharmaceuticals's employee count trend over the years:

Employee count trend for Rhythm Pharmaceuticals

Uncover Rhythm Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rhythm Pharmaceuticals include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Rhythm Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Venrock, Foresite Capital & 9 others	70/100
10th	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100